Several large cardiovascular outcome trials have demonstrated that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk of cardiovascular disease in type 2 diabetes [8,9,10,11]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.